Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Risedronate sodium
20 general benefit · 3 not a benefit
Teva-Risedronate · DIN 02298376 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Risedronate · DIN 02298376
Manufacturer: Teva Canada Limited; listing date 2010-04-23
Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 5 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Risedronate: Formulary list price $1.84 per unit (the source does not state the unit; exact figure $1.8445). What the ministry pays, not the patient.
Ministry pays: $1.8445 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298376)
Source record
DIN 02298376: Teva-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000372; group id 954; item number 2263; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.8445; ministry $1.8445
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298376
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78367
Interchangeable products
Actonel · DIN 02242518 · not recorded
Shortage status: resolved shortage (ended June 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298376
Shortage record checked October 6, 2026
Teva-Risedronate · DIN 02298384 · 30 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Risedronate · DIN 02298384
Manufacturer: Teva Canada Limited; listing date 2010-04-23
Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 30 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Risedronate: Formulary list price $11.38 per unit (the source does not state the unit; exact figure $11.3807). What the ministry pays, not the patient.
Ministry pays: $11.3807 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298384)
Source record
DIN 02298384: Teva-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000340; group id 954; item number 2264; lccId None; manufacturer id TEV
Source form: Tab; strength: 30mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.3807; ministry $11.3807
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298384
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78368
Interchangeable products
Actonel · DIN 02239146 · not recorded
Shortage status: discontinued (April 7, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298384
Shortage record checked October 6, 2026
AA-Risedronate DR · DIN 02493268 · 35 mg · DR tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
AA-Risedronate DR · DIN 02493268
Manufacturer: A A Pharma Inc.; listing date 2021-07-30
Health Canada: Marketed since 2023-09-08 · brand AA-RISEDRONATE DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAA-Risedronate DR: Formulary list price $2.97 per unit (the source does not state the unit; exact figure $2.9663). What the ministry pays, not the patient.
Ministry pays: $2.9663 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493268)
Source record
DIN 02493268: AA-Risedronate DR
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000656; group id 954; item number 2262; lccId None; manufacturer id AAP
Source form: DR Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.9663; ministry $2.9663
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493268
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98324
Interchangeable products
Actonel DR · DIN 02370417 · $2.9663
Shortage status: resolved shortage (ended March 11, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02493268
Shortage record checked October 6, 2026
Actonel DR · DIN 02370417 · 35 mg · DR tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Actonel DR (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Actonel DR · DIN 02370417
Manufacturer: Warner Chilcott Canada Co.; listing date 2012-02-29
Health Canada: Marketed since 2025-05-22 · brand ACTONEL DR · ATC M05BA07 RISEDRONIC ACID · form Tablet (delayed-release) · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $2.9663 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370417)
Source record
DIN 02370417: Actonel DR
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000656; group id 954; item number 2262; lccId None; manufacturer id WAR
Source form: DR Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.8653; ministry $2.9663
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370417
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85557
Interchangeable products
AA-Risedronate DR · DIN 02493268 · $2.9663
Shortage status: resolved shortage (ended June 18, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370417
Shortage record checked October 6, 2026
Apo-Risedronate · DIN 02353687 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Risedronate · DIN 02353687
Manufacturer: Apotex Inc.; listing date 2010-10-28
Health Canada: Marketed since 2012-06-20 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02353687)
Source record
DIN 02353687: Apo-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id APX
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353687
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83888
Interchangeable products
Actonel · DIN 02246896 · not recorded
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended December 20, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353687
Shortage record checked October 6, 2026
Auro-Risedronate · DIN 02406306 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Risedronate · DIN 02406306
Manufacturer: Auro Pharma Inc.; listing date 2013-09-27
Health Canada: Marketed since 2013-07-08 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02406306)
Source record
DIN 02406306: Auro-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id AUR
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02406306
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89102
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended November 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02406306
Shortage record checked October 6, 2026
PMS-Risedronate · DIN 02302209 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Risedronate · DIN 02302209
Manufacturer: Pharmascience Inc.; listing date 2010-10-28
Health Canada: Marketed since 2010-07-27 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02302209)
Source record
DIN 02302209: PMS-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id PMS
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02302209
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78754
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended August 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02302209
Shortage record checked October 6, 2026
Risedronate · DIN 02370255 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Risedronate · DIN 02370255
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Marketed since 2025-02-13 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRisedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370255)
Source record
DIN 02370255: Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SAI
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370255
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85541
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended March 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02370255
Shortage record checked October 6, 2026
Risedronate · DIN 02411407 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Risedronate · DIN 02411407
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-05-29
Health Canada: Marketed since 2024-02-01 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRisedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411407)
Source record
DIN 02411407: Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SIV
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411407
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89602
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended February 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411407
Shortage record checked October 6, 2026
Riva-Risedronate · DIN 02341077 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Riva-Risedronate · DIN 02341077
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2010-07-28 · brand RIVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Laboratoire riva inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRiva-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02341077)
Source record
DIN 02341077: Riva-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id RIA
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02341077
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82662
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02341077
Shortage record checked October 6, 2026
Sandoz Risedronate · DIN 02327295 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Risedronate · DIN 02327295
Manufacturer: Sandoz Canada Inc.; listing date 2010-10-28
Health Canada: Marketed since 2010-07-28 · brand SANDOZ RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSandoz Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02327295)
Source record
DIN 02327295: Sandoz Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id SDZ
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02327295
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81259
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended March 11, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02327295
Shortage record checked October 6, 2026
Teva-Risedronate · DIN 02298392 · 35 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Risedronate · DIN 02298392
Manufacturer: Teva Canada Limited; listing date 2010-04-23
Health Canada: Marketed since 2011-06-03 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02298392)
Source record
DIN 02298392: Teva-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id TEV
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02298392
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78369
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Shortage status: resolved shortage (ended February 5, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298392
Shortage record checked October 6, 2026
Actonel · DIN 02316838 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Actonel · DIN 02316838
Manufacturer: Warner Chilcott Canada Co.; listing date 2009-06-23
Health Canada: Marketed since 2025-05-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02316838)
Source record
DIN 02316838: Actonel
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id WAR
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $47.3370; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02316838
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80233
Interchangeable products
Apo-Risedronate · DIN 02377721 · $11.1875
Auro-Risedronate · DIN 02442760 · $11.1875
PMS-Risedronate · DIN 02424177 · $11.1875
Risedronate · DIN 02528460 · $11.1875
Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02316838
Shortage record checked October 6, 2026
Apo-Risedronate · DIN 02377721 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Risedronate · DIN 02377721
Manufacturer: Apotex Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-05-17 · brand APO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.
Ministry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02377721)
Source record
DIN 02377721: Apo-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id APX
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.1875; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02377721
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86354
Interchangeable products
Actonel · DIN 02316838 · $11.1875
Auro-Risedronate · DIN 02442760 · $11.1875
PMS-Risedronate · DIN 02424177 · $11.1875
Risedronate · DIN 02528460 · $11.1875
Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended March 4, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02377721
Shortage record checked October 6, 2026
PMS-Risedronate · DIN 02424177 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Risedronate · DIN 02424177
Manufacturer: Pharmascience Inc.; listing date 2014-07-30
Health Canada: Marketed since 2014-05-28 · brand PMS-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.
Ministry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02424177)
Source record
DIN 02424177: PMS-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id PMS
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.1875; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424177
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90889
Interchangeable products
Actonel · DIN 02316838 · $11.1875
Apo-Risedronate · DIN 02377721 · $11.1875
Auro-Risedronate · DIN 02442760 · $11.1875
Risedronate · DIN 02528460 · $11.1875
Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended March 9, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424177
Shortage record checked October 6, 2026
Risedronate · DIN 02528460 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Risedronate · DIN 02528460
Manufacturer: Sanis Health Inc.; listing date 2022-11-30
Health Canada: Marketed since 2022-10-05 · brand RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRisedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.
Ministry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02528460)
Source record
DIN 02528460: Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id SAI
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.1875; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02528460
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101771
Interchangeable products
Actonel · DIN 02316838 · $11.1875
Apo-Risedronate · DIN 02377721 · $11.1875
Auro-Risedronate · DIN 02442760 · $11.1875
PMS-Risedronate · DIN 02424177 · $11.1875
Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: resolved shortage (ended April 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02528460
Shortage record checked October 6, 2026
Teva-Risedronate · DIN 02413809 · 150 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Risedronate · DIN 02413809
Manufacturer: Teva Canada Limited; listing date 2014-01-03
Health Canada: Marketed since 2013-10-10 · brand TEVA-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 150 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.
Ministry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02413809)
Source record
DIN 02413809: Teva-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id TEV
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.1875; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02413809
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89845
Interchangeable products
Actonel · DIN 02316838 · $11.1875
Apo-Risedronate · DIN 02377721 · $11.1875
Auro-Risedronate · DIN 02442760 · $11.1875
PMS-Risedronate · DIN 02424177 · $11.1875
Risedronate · DIN 02528460 · $11.1875
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413809
Shortage record checked October 6, 2026
Actonel · DIN 02246896 · 35 mg · tablet
Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Actonel · DIN 02246896
Manufacturer: Warner Chilcott Canada Co.; listing date 2003-04-16
Health Canada: Marketed since 2025-03-05 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordActonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246896)
Source record
DIN 02246896: Actonel
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id WAR
Source form: Tab; strength: 35mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246896
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71123
Interchangeable products
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: resolved shortage (ended October 11, 2019); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246896
Shortage record checked October 6, 2026
Auro-Risedronate · DIN 02442760 · 150 mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Risedronate · DIN 02442760
Manufacturer: Auro Pharma Inc.; listing date 2018-04-30
Health Canada: Dormant since 2020-07-24 · brand AURO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 150 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Risedronate: Formulary list price $11.19 per unit (the source does not state the unit; exact figure $11.1875). What the ministry pays, not the patient.
Ministry pays: $11.1875 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442760)
Source record
DIN 02442760: Auro-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000595; group id 954; item number 2266; lccId None; manufacturer id AUR
Source form: Tab; strength: 150mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $11.1875; ministry $11.1875
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442760
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92715
Interchangeable products
Actonel · DIN 02316838 · $11.1875
Apo-Risedronate · DIN 02377721 · $11.1875
PMS-Risedronate · DIN 02424177 · $11.1875
Risedronate · DIN 02528460 · $11.1875
Teva-Risedronate · DIN 02413809 · $11.1875
Shortage status: active shortage (reported March 5, 2019, last updated March 6, 2019) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442760
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 24, 2020 — choose a marketed DIN from the same-category list.
Jamp-Risedronate · DIN 02368552 · 35 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued September 6, 2022 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp-Risedronate · DIN 02368552
Manufacturer: Jamp Pharma Corporation; listing date 2012-08-27
Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02368552)
Source record
DIN 02368552: Jamp-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id JPC
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02368552
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85353
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Ratio-Risedronate · DIN 02319861 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: active shortage (reported November 1, 2019, estimated to end December 30, 2022, last updated April 7, 2021) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02368552
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 6, 2022 — choose a marketed DIN from the same-category list.
Ratio-Risedronate · DIN 02319861 · 35 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.Discontinued October 26, 2015 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2015-10-26 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ratio-Risedronate · DIN 02319861
Manufacturer: Ratiopharm Inc.; listing date 2010-10-28
Health Canada: Cancelled post market since 2015-10-26 · brand RATIO-RISEDRONATE · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35 MG · company Ratiopharm inc division of teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRatio-Risedronate: Formulary list price $1.68 per unit (the source does not state the unit; exact figure $1.6764). What the ministry pays, not the patient.
Ministry pays: $1.6764 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02319861)
Source record
DIN 02319861: Ratio-Risedronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000430; group id 954; item number 2265; lccId None; manufacturer id RPH
Source form: Tab; strength: 35mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6764; ministry $1.6764
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02319861
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80533
Interchangeable products
Actonel · DIN 02246896 · not recorded
Apo-Risedronate · DIN 02353687 · $1.6764
Auro-Risedronate · DIN 02406306 · $1.6764
Jamp-Risedronate · DIN 02368552 · $1.6764
PMS-Risedronate · DIN 02302209 · $1.6764
Risedronate · DIN 02370255 · $1.6764
Risedronate · DIN 02411407 · $1.6764
Riva-Risedronate · DIN 02341077 · $1.6764
Sandoz Risedronate · DIN 02327295 · $1.6764
Teva-Risedronate · DIN 02298392 · $1.6764
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02319861
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 26, 2015 — choose a marketed DIN from the same-category list.
Actonel · DIN 02242518 · 5 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued January 4, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Actonel · DIN 02242518
Manufacturer: Warner Chilcott Canada Co.; listing date 2001-03-07
Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 5 MG · company Allergan pharma co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordActonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242518)
Source record
DIN 02242518: Actonel
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 920000372; group id 954; item number 2263; lccId None; manufacturer id WAR
Source form: Tab; strength: 5mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242518
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66266
Interchangeable products
Teva-Risedronate · DIN 02298376 · $1.8445
Shortage status: active shortage (reported not recorded, last updated December 20, 2018) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242518
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 4, 2019 — choose a marketed DIN from the same-category list.
Actonel · DIN 02239146 · 30 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.Discontinued January 4, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-04 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Actonel · DIN 02239146
Manufacturer: Warner Chilcott Canada Co.; listing date 2000-04-17
Health Canada: Cancelled post market since 2019-01-04 · brand ACTONEL · ATC M05BA07 RISEDRONIC ACID · form Tablet · route Oral · ingredients RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 30 MG · company Allergan pharma co. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordActonel: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239146)
Source record
DIN 02239146: Actonel
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 920000340; group id 954; item number 2264; lccId None; manufacturer id WAR
Source form: Tab; strength: 30mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239146
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62602
Interchangeable products
Teva-Risedronate · DIN 02298384 · $11.3807
Shortage status: discontinued (January 20, 2017, reported by ALLERGAN PHARMA CO.); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02239146
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 4, 2019 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (M05B, M05BA): coverage varies; not interchangeable
- Alendronate (Fosamax): general benefit, not a benefit
- Clodronate (Ostac): limited Use 280, 358, 359, not a benefit
- Etidronate (Didronel): limited Use 236, 237, not a benefit
- Zoledronic acid (Aclasta): limited Use 319, 436, 523, not a benefit
- Pamidronate (Aredia): not a benefit
- Alendronate + cholecalciferol (Fosavance): general benefit
1 more in the class list below
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered
Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE
Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL
92:00 UNCLASSIFIED THERAPEUTIC AGENTS
· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab
· 2 products · Listed, not a benefit (1),
Limited Use, codes 280, 358, 359 (1) · strengths: 400mg · Cap
· 2 products · Listed, not a benefit (1),
Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab
· 12 products ·
Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)
· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial
· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab
· 8 products ·
Limited Use, codes 687, 688 (4),
Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)
· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab
· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L
· 3 products · General benefit · strengths: 50mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab
· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00
and 78 more
Full class listing
Related classes:
Same formulary class, not same indication: class membership alone does not establish equivalent uses.